17
Participants
Start Date
May 10, 2019
Primary Completion Date
August 16, 2023
Study Completion Date
March 5, 2025
Selinexor
"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
Huntsman Cancer Institute/University of Utah, Salt Lake City
Collaborators (1)
Karyopharm Therapeutics Inc
INDUSTRY
University of Utah
OTHER